---
document_datetime: 2025-12-17 23:10:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/carbaglu.html
document_name: carbaglu.html
version: success
processing_time: 0.1330819
conversion_datetime: 2025-12-28 14:41:51.705535
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Carbaglu

[RSS](/en/individual-human-medicine.xml/65981)

##### Authorised

This medicine is authorised for use in the European Union

carglumic acid Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-81949)
- [More information on Carbaglu](#more-information-on-carbaglu-579)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Carbaglu. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Carbaglu.

Expand section

Collapse section

## What is Carbaglu?

Carbaglu is a medicine that contains the active substance carglumic acid. It is available as dispersible tablets. 'Dispersible' means that the tablets can be dispersed (mixed) in water.

## What is Carbaglu used for?

Carbaglu is used for the treatment of hyperammonaemia (high blood levels of ammonia) in patients with the following metabolic diseases:

- N-acetylglutamate synthase (NAGS) deficiency. Patients with this lifelong disease lack a liver enzyme called NAGS, which normally helps to break down ammonia. If the enzyme is not present, ammonia cannot be broken down and it builds up in the blood;
- some organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia) where patients lack certain enzymes involved in protein metabolism.

Because the number of patients with these diseases is low, they are considered 'rare' and Carbaglu was designated an 'orphan medicine' (a medicine used in rare diseases) on various dates (see below).

The medicine can only be obtained with a prescription.

## How is Carbaglu used?

Carbaglu treatment should be started by a doctor who has experience in treating patients with metabolic diseases.

In patients with NAGS deficiency, treatment may be started as early as the first day of life and the medicine is used for the patient's whole life. In patients with organic acidaemias, treatment is started when the patient has a hyperammonaemia crisis and continued until the crisis is finished.

The initial daily dose of Carbaglu should be 100 mg per kilogram body weight, but up to 250 mg/kg can be used if necessary. The dose should then be adjusted to maintain normal blood ammonia levels. The tablets should be dispersed (mixed) in a small amount of water before being given to the patient. They can easily be broken into two equal halves.

## How does Carbaglu work?

When ammonia builds up in the blood, it is toxic to the body, especially the brain. Carbaglu is very similar in structure to N-acetylglutamate, which activates an enzyme that breaks down ammonia. Carbaglu therefore helps break down ammonia, reducing ammonia blood levels and its toxic effects.

## How has Carbaglu been studied?

Carbaglu has been studied in 20 patients, 12 of whom had NAGS deficiency and were treated for an average of about three years. The other eight patients were treated for hyperammonaemia of another cause. The company also presented information from the published literature on a further four patients treated with the active substance in Carbaglu.

Carbaglu has also been studied in 57 patients (about two-thirds were newborn babies) with isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia who were treated with Carbaglu during hyperammonaemia crises.

In all of the studies, the main measure of effectiveness was the change in ammonia levels in the blood.

## What benefit has Carbaglu shown during the studies?

In patients with NAGS deficiency, ammonia levels were brought back to normal after Carbaglu treatment. Patients on Carbaglu could be kept stable without a need for restrictions to the diet or the use of other medicines.

In patients with isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia, Carbaglu also induced a decrease in ammonia levels in the blood, following an average of 5.5 days of treatment.

## What is the risk associated with Carbaglu?

The most common side effect with Carbaglu (seen in between 1 and 10 patients in 100) is increased sweating. For the full list of side effects reported with Carbaglu, see the package leaflet.

Carbaglu should not be used in people who may be hypersensitive (allergic) to carglumic acid or any of the other ingredients. Carbaglu must not be used in women who are breastfeeding.

## Why has Carbaglu been approved?

The CHMP concluded that Carbaglu was effective in reducing blood ammonia to normal levels and decided that Carbaglu's benefits are greater than its risks. The Committee recommended that Carbaglu be given marketing authorisation.

## Other information about Carbaglu

The European Commission granted a marketing authorisation valid throughout the European Union for Carbaglu to Orphan Europe on 24 January 2003. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Carbaglu, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Carbaglu : EPAR - Summary for the public

English (EN) (71.27 KB - PDF)

**First published:** 08/04/2009

**Last updated:** 19/07/2011

[View](/en/documents/overview/carbaglu-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-998)

български (BG) (173.84 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/bg/documents/overview/carbaglu-epar-summary-public_bg.pdf)

español (ES) (134.98 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/es/documents/overview/carbaglu-epar-summary-public_es.pdf)

čeština (CS) (161.97 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/cs/documents/overview/carbaglu-epar-summary-public_cs.pdf)

dansk (DA) (134.39 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/da/documents/overview/carbaglu-epar-summary-public_da.pdf)

Deutsch (DE) (151.92 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/de/documents/overview/carbaglu-epar-summary-public_de.pdf)

eesti keel (ET) (133.75 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/et/documents/overview/carbaglu-epar-summary-public_et.pdf)

ελληνικά (EL) (174.55 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/el/documents/overview/carbaglu-epar-summary-public_el.pdf)

français (FR) (135.07 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/fr/documents/overview/carbaglu-epar-summary-public_fr.pdf)

italiano (IT) (135.55 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/it/documents/overview/carbaglu-epar-summary-public_it.pdf)

latviešu valoda (LV) (161.79 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/lv/documents/overview/carbaglu-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (160.41 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/lt/documents/overview/carbaglu-epar-summary-public_lt.pdf)

magyar (HU) (157.75 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/hu/documents/overview/carbaglu-epar-summary-public_hu.pdf)

Malti (MT) (100.7 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/mt/documents/overview/carbaglu-epar-summary-public_mt.pdf)

Nederlands (NL) (134.81 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/nl/documents/overview/carbaglu-epar-summary-public_nl.pdf)

polski (PL) (160.97 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/pl/documents/overview/carbaglu-epar-summary-public_pl.pdf)

português (PT) (134.37 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/pt/documents/overview/carbaglu-epar-summary-public_pt.pdf)

română (RO) (158.76 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/ro/documents/overview/carbaglu-epar-summary-public_ro.pdf)

slovenčina (SK) (160.39 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/sk/documents/overview/carbaglu-epar-summary-public_sk.pdf)

slovenščina (SL) (156.4 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/sl/documents/overview/carbaglu-epar-summary-public_sl.pdf)

Suomi (FI) (133.58 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/fi/documents/overview/carbaglu-epar-summary-public_fi.pdf)

svenska (SV) (133.42 KB - PDF)

**First published:**

08/04/2009

**Last updated:**

19/07/2011

[View](/sv/documents/overview/carbaglu-epar-summary-public_sv.pdf)

Carbaglu : EPAR - Risk management plan summary

English (EN) (106.82 KB - PDF)

**First published:** 19/07/2023

[View](/en/documents/rmp-summary/carbaglu-epar-risk-management-plan-summary_en.pdf)

## Product information

Carbaglu : EPAR - Product Information

English (EN) (380.83 KB - PDF)

**First published:** 21/09/2009

**Last updated:** 09/12/2025

[View](/en/documents/product-information/carbaglu-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-326)

български (BG) (449.94 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/bg/documents/product-information/carbaglu-epar-product-information_bg.pdf)

español (ES) (309.14 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/es/documents/product-information/carbaglu-epar-product-information_es.pdf)

čeština (CS) (436.66 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/cs/documents/product-information/carbaglu-epar-product-information_cs.pdf)

dansk (DA) (377.37 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/da/documents/product-information/carbaglu-epar-product-information_da.pdf)

Deutsch (DE) (310.16 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/de/documents/product-information/carbaglu-epar-product-information_de.pdf)

eesti keel (ET) (302.16 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/et/documents/product-information/carbaglu-epar-product-information_et.pdf)

ελληνικά (EL) (394.65 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/el/documents/product-information/carbaglu-epar-product-information_el.pdf)

français (FR) (356.74 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/fr/documents/product-information/carbaglu-epar-product-information_fr.pdf)

hrvatski (HR) (351.11 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/hr/documents/product-information/carbaglu-epar-product-information_hr.pdf)

íslenska (IS) (317.4 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/is/documents/product-information/carbaglu-epar-product-information_is.pdf)

italiano (IT) (357.05 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/it/documents/product-information/carbaglu-epar-product-information_it.pdf)

latviešu valoda (LV) (359.54 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/lv/documents/product-information/carbaglu-epar-product-information_lv.pdf)

lietuvių kalba (LT) (353.31 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/lt/documents/product-information/carbaglu-epar-product-information_lt.pdf)

magyar (HU) (365.15 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/hu/documents/product-information/carbaglu-epar-product-information_hu.pdf)

Malti (MT) (384.93 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/mt/documents/product-information/carbaglu-epar-product-information_mt.pdf)

Nederlands (NL) (309.76 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/nl/documents/product-information/carbaglu-epar-product-information_nl.pdf)

norsk (NO) (306.73 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/no/documents/product-information/carbaglu-epar-product-information_no.pdf)

polski (PL) (366.79 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/pl/documents/product-information/carbaglu-epar-product-information_pl.pdf)

português (PT) (301.52 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/pt/documents/product-information/carbaglu-epar-product-information_pt.pdf)

română (RO) (365.86 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/ro/documents/product-information/carbaglu-epar-product-information_ro.pdf)

slovenčina (SK) (354.74 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/sk/documents/product-information/carbaglu-epar-product-information_sk.pdf)

slovenščina (SL) (349.11 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/sl/documents/product-information/carbaglu-epar-product-information_sl.pdf)

Suomi (FI) (277.18 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/fi/documents/product-information/carbaglu-epar-product-information_fi.pdf)

svenska (SV) (296.14 KB - PDF)

**First published:**

21/09/2009

**Last updated:**

09/12/2025

[View](/sv/documents/product-information/carbaglu-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000291322 25/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Carbaglu : EPAR - All Authorised presentations

English (EN) (25.9 KB - PDF)

**First published:** 10/11/2006

**Last updated:** 04/08/2018

[View](/en/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-107)

български (BG) (28.37 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/bg/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.33 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/es/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_es.pdf)

čeština (CS) (27.14 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/cs/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/da/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.84 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/de/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.55 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/et/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (28.93 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/el/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_el.pdf)

français (FR) (25.84 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/fr/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.69 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/hr/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.97 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/is/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.75 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/it/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.77 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/lv/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.97 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/lt/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/hu/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (26.77 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/mt/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.96 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/nl/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.45 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/no/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_no.pdf)

polski (PL) (31.92 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/pl/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.69 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/pt/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_pt.pdf)

română (RO) (26 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/ro/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (27.54 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/sk/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.14 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/sl/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.78 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/fi/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.95 KB - PDF)

**First published:**

10/11/2006

**Last updated:**

04/08/2018

[View](/sv/documents/all-authorised-presentations/carbaglu-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Carbaglu Active substance carglumic acid International non-proprietary name (INN) or common name carglumic acid Therapeutic area (MeSH)

- Amino Acid Metabolism, Inborn Errors
- Propionic Acidemia

Anatomical therapeutic chemical (ATC) code A16AA05

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Carbaglu is indicated in treatment of:

- hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;
- hyperammonaemia due to isovaleric acidaemia;
- hyperammonaemia due to methymalonic acidaemia;
- hyperammonaemia due to propionic acidaemia.

## Authorisation details

EMA product number EMEA/H/C/000461 Marketing authorisation holder

Tour Hekla

Tour Hekla 52 avenue du Général de Gaulle F-92800 Puteaux France

Marketing authorisation issued 24/01/2003 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Carbaglu : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.67 KB - PDF)

**First published:** 09/12/2025

[View](/en/documents/procedural-steps-after/carbaglu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Carbaglu : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (157.12 KB - PDF)

**First published:** 21/09/2009

**Last updated:** 09/12/2025

[View](/en/documents/procedural-steps-after/carbaglu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Carbaglu-H-C-PSUSA-564-201501 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/713568/2015

English (EN) (69.38 KB - PDF)

**First published:** 02/03/2016

**Last updated:** 02/03/2016

[View](/en/documents/scientific-conclusion/carbaglu-h-c-psusa-564-201501-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Carbaglu-H-C-461-II-0013 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/532759/2016

English (EN) (1.94 MB - PDF)

**First published:** 19/07/2011

**Last updated:** 19/09/2016

[View](/en/documents/variation-report/carbaglu-h-c-461-ii-0013-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Carbaglu

Adopted

Reference Number: EMA/CHMP/306613/2011

English (EN) (50.3 KB - PDF)

**First published:** 15/04/2011

**Last updated:** 15/04/2011

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-carbaglu_en.pdf)

## Initial marketing authorisation documents

Carbaglu : EPAR - Scientific Discussion

English (EN) (244.86 KB - PDF)

**First published:** 10/11/2006

**Last updated:** 10/11/2006

[View](/en/documents/scientific-discussion/carbaglu-epar-scientific-discussion_en.pdf)

Carbaglu : EPAR - Procedural steps taken before authorisation

English (EN) (91.29 KB - PDF)

**First published:** 10/11/2006

**Last updated:** 10/11/2006

[View](/en/documents/procedural-steps/carbaglu-epar-procedural-steps-taken-authorisation_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Carbaglu : EPAR - Product information - tracked changes

English (EN) (199 KB - DOC)

**First published:** 09/12/2025

[View](/en/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-649)

български (BG) (87.52 KB - DOCX)

**First published:**

09/12/2025

[View](/bg/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_bg.docx)

español (ES) (86.69 KB - DOCX)

**First published:**

09/12/2025

[View](/es/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_es.docx)

čeština (CS) (90.1 KB - DOCX)

**First published:**

09/12/2025

[View](/cs/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (83.41 KB - DOCX)

**First published:**

09/12/2025

[View](/da/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (85.77 KB - DOCX)

**First published:**

09/12/2025

[View](/de/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (84.42 KB - DOCX)

**First published:**

09/12/2025

[View](/et/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (95.24 KB - DOCX)

**First published:**

09/12/2025

[View](/el/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_el.docx)

français (FR) (86.36 KB - DOCX)

**First published:**

09/12/2025

[View](/fr/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (97.37 KB - DOCX)

**First published:**

09/12/2025

[View](/hr/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (90.24 KB - DOCX)

**First published:**

09/12/2025

[View](/is/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_is.docx)

italiano (IT) (82.89 KB - DOCX)

**First published:**

09/12/2025

[View](/it/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (86.71 KB - DOCX)

**First published:**

09/12/2025

[View](/lv/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (77.72 KB - DOCX)

**First published:**

09/12/2025

[View](/lt/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (89.65 KB - DOCX)

**First published:**

09/12/2025

[View](/hu/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (86.86 KB - DOCX)

**First published:**

09/12/2025

[View](/mt/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (83.21 KB - DOCX)

**First published:**

09/12/2025

[View](/nl/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (88.72 KB - DOCX)

**First published:**

09/12/2025

[View](/no/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_no.docx)

polski (PL) (84.77 KB - DOCX)

**First published:**

09/12/2025

[View](/pl/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_pl.docx)

português (PT) (86.12 KB - DOCX)

**First published:**

09/12/2025

[View](/pt/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_pt.docx)

română (RO) (90.16 KB - DOCX)

**First published:**

09/12/2025

[View](/ro/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (87.98 KB - DOCX)

**First published:**

09/12/2025

[View](/sk/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (82.23 KB - DOCX)

**First published:**

09/12/2025

[View](/sl/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (74.15 KB - DOCX)

**First published:**

09/12/2025

[View](/fi/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (83.88 KB - DOCX)

**First published:**

09/12/2025

[View](/sv/documents/product-information-tracked-changes/carbaglu-epar-product-information-tracked-changes_sv.docx)

#### More information on Carbaglu

This product is no longer an orphan medicine.

This product originally had an orphan designation for the treatment of [n-acetylglutamate synthetase (NAGS) deficiency](/en/medicines/human/orphan-designations/eu-3-00-007) , granted on 18 October 2000. This designation was withdrawn from the Community register of orphan medicinal products in January 2013 at the end of the 10-year period of market exclusivity.

This product was also designated an orphan medicine for the following orphan indications:

- [treatment of isovaleric acidaemia](/en/medicines/human/orphan-designations/eu-3-08-575) (7 November 2008);
- [treatment of methylmalonic acidaemia](/en/medicines/human/orphan-designations/eu-3-08-576) (7 November 2008);
- [treatment of propionic acidaemia](/en/medicines/human/orphan-designations/eu-3-08-577) (7 November 2008).
- The above designations were withdrawn from the Community register of orphan medicinal products in June 2021 at the end of the 10-year period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/12/2025

## Share this page

[Back to top](#main-content)